| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
4 analysts have shared their evaluations of Cardiff Oncology (NASDAQ:CRDF) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 0 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $12.62, a high estimate of $19.00, and a low estimate of $3.50. Observing a downward trend, the current average is 27.89% lower than the prior average price target of $17.50.
The standing of Cardiff Oncology among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Robert Burns | HC Wainwright & Co. | Lowers | Buy | $10.00 | $18.00 |
| Kevin DeGeeter | Ladenburg Thalmann | Announces | Buy | $19.00 | - |
| Maury Raycroft | Jefferies | Announces | Hold | $3.50 | - |
| Robert Burns | HC Wainwright & Co. | Raises | Buy | $18.00 | $17.00 |
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Cardiff Oncology's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Cardiff Oncology analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Cardiff Oncology's financials over 3M reveals challenges. As of 30 June, 2025, the company experienced a decline of approximately -25.77% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Cardiff Oncology's net margin excels beyond industry benchmarks, reaching -11528.1%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Cardiff Oncology's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -21.55%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Cardiff Oncology's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -17.38%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CRDF
